Background: Background & Aims: The seroprevalence of the Hepatitis E virus (HEV) and its chronicity rate in the HIV-infected population has not been well established. Consequently, the magnitude of this emerging disease in this population cannot be established. The objective of our study was to evaluate the serological/virological HEV situation and factors associated with it in HIV-infected patients. Methodology: Prospective study in Southern Spain that included HIV-infected patients who were followed up between September 2012 and May 2013. All patients included were tested for anti-HEV IgG/IgM. In those patients with confirmed anti-HEV IgG/IgM positivity, a RT-PCR was performed. In patients where HEV-RNA was amplified, a second RT-PCR was performed 6 months later to identify transient or chronic HEV infections. Additionally, we performed a RT-PCR in all patients with CD4+ cell counts that were lower than 200 cells/mL regardless of the anti-HEV IgG/IgM status. HEV seroprevalence and its associated factors were evaluated. Results: Eight-hundred and ninety-four HIV infected patients were enrolled in the study. Of these patients, 399 (44.6%) were monoinfected with HIV; 462 (51.6%) were co-infected with HIV/HCV; 12 (1.3%) were co-infected with HIV/HBV; and 21 (2.3%) were coo-infected with HIV/HCV/HBV. In 88 patients, anti-HEV IgG/IgM (86 IgG+/IgM- and 2 IgG+/IgM+) were detected, and consequently, the overall HEV seroprevalence in our population was 9.8% (95% CI: 8.02%-11.9%). The anti-HEV IgG/IgM positive patients were older than those with serum that was anti-HEV IgG negative (p < 0.001). In the logistic multivariate analysis model, only age was associated with a positive anti-HEV IgG/IgM status (OR = 1.053; 95% CI: 1.017-1.091). When patients were sorted according to hepatitis virus co-infection, serum anti-HEV IgG/IgM was detected in 40 HIV monoinfected patients (10.03%; 95% CI: 7.3%-13.3%) and in 48 HIV/hepatotropic virus co-infected patients (9.7%; 95% CI: 7.3%-12.5%). However, no difference in the seroprevalence was found between the groups (p = 0.866). In five patients (0.5%; 95% CI: 0.2%-1.2%), RNA-HEV was detected, which indicated 5.7% (95% CI: 2.1%-12.1%) anti-HEV IgG/ IgM-positive patients; however, none of those patients had detectable HEV-RNA six months later. None of the 98 anti-HEV IgG/IgM negative patients with a CD4+ cell count lower than 200 cells/mL had detectable HEV-RNA. Conclusions: Our study found that despite HEV infection is frequent in HIV-infected patients, the detection of HEV-RNA in our study was low, and no development of chronic infection was found. Furthermore, in immunosuppressed patients with the absence of HEV-serum-marker positivity, HEV-RNA was not detected.